Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

Dependence of Histone Modifications and Gene Expression on DNA Hypermethylation in Cancer

Jill A. Fahrner, Sayaka Eguchi, James G. Herman and Stephen B. Baylin
Jill A. Fahrner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sayaka Eguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James G. Herman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen B. Baylin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Map of histone H3 modifications along a hypermethylated versus an unmethylated hMLH1 promoter. A, schematic of the hMLH1 promoter. The vertical lines represent the location of CpG dinucleotides, and the arrow indicates the approximate position of the transcription start site. The CpG island extends 3′ from ∼−800 (relative to the transcription start site) into exon 1. The doubled horizontal line denotes the region examined by MSP. In SW480 cells, the promoter is unmethylated, and the gene is expressed. However in RKO cells, the promoter is hypermethylated, and the gene is silenced. The horizontal bars below the schematic indicate the location of the DNA fragments amplified by PCR done on the DNA recovered from ChIP experiments. The broken bars denote the primer sets used in the time course experiments. B, D, and F, enrichment of hMLH1 promoter DNA immunoprecipitated with antibodies specific for acetylated histone H3 (K9 and K14), dimethyl-H3-K4, and dimethyl-H3-K9, respectively. Points on the graphs represent data from the corresponding DNA fragment amplified by PCR, as shown at the bottom A. The value of each point was calculated as the average from two independent ChIP experiments and a total of four independent PCR analyses. Each error bar indicates the SD from the mean. □ represent data from SW480. ▪ represent data from RKO. C, E, and G, representative PCR analyses of ChIP on RKO and SW480 from areas typical of enrichment for acetylated H3, methyl-H3-K4, and methyl-H3-K9, respectively. Multiplex PCR was performed on bound (B) immunoprecipitated DNA and input (I) nonimmunoprecipitated DNA with each hMLH1 primer set.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Inhibition of histone deacetylation by TSA fails to dramatically alter key components of the histone code map along the hypermethylated hMLH1 promoter. ChIP was done on RKO cells after treatment with 300 nm TSA for 24 h. A, C, and E, enrichment of acetylated histone H3 (K9 and K14), dimethyl-H3-K4, and dimethyl-H3-K9, respectively, at the hMLH1 promoter. ○ represents enrichment in RKO cells treated with TSA. • represents data from untreated RKO cells. Points on each graph represent data from the corresponding DNA fragment amplified by PCR, as illustrated in Fig. 1A<$REFLINK> . The value of each point was calculated as the average from two independent ChIP experiments and a total of four independent PCR analyses. Each error bar indicates the SD from the mean. B, D, and F, representative PCR analyses of ChIP performed on RKO cells, before and after treatment with TSA, from areas typical of enrichment for acetylated H3, methyl-H3-K4, and methyl-H3-K9, respectively. Bound DNA (B) and input DNA (I) were coamplified with primers for hMLH1 and GAPDH.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Inhibition of DNA methylation by 5-Aza-dC completely reverses all examined components of the histone code map along the hypermethylated hMLH1 promoter. ChIP was performed on RKO cells after treatment with 1 μm 5-Aza-dC for 5 days. A, C, and E, enrichment of hMLH1 promoter DNA precipitated by antibodies specific for acetylated histone H3 (K9 and K14), dimethyl-H3-K4, and dimethyl-H3-K9, respectively. ○ represents enrichment in RKO cells treated with 5-Aza-dC. • represents data from untreated RKO cells. The value of each point was calculated as the average from two (untreated) or three (drug-treated) independent ChIP experiments and four independent PCR analyses from each untreated or drug-treated experiment. Each error bar indicates the SD from the mean. Points on each graph correspond to the overlapping DNA fragments amplified by PCR as depicted in Fig. 1A. B, D, and F<$REFLINK> , representative PCR analyses of ChIP done on RKO cells, with or without treatment with 5-Aza-dC, from areas typical of enrichment for acetylated H3, methyl-H3-K4, and methyl-H3-K9, respectively. DNA from bound (B) and input (I) fractions were coamplified with primers for hMLH1 and GAPDH.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Treatment with 5-Aza-dC reverses all components of the histone code examined at a hypermethylated hMLH1 promoter by 48 h. The data represent two independent time course experiments in which RKO cells were treated with 1 μm 5-Aza-dC (or mock-treated) and harvested at each time point shown for ChIP analysis. A total of four to seven PCR analyses were performed on the immunoprecipitated DNA from each time point. Each point on the graphs represents the average value of enrichment, and each error bar indicates the SD from the mean. ○ represents data from RKO cells treated with 5-Aza-dC. • represents data from mock-treated RKO cells. Data from a 5-day time point served as positive controls to ensure that drug treatment was effective. The broken horizontal bars under the hMLH1 promoter schematic in Fig. 1A<$REFLINK> indicate the location of the primer sets used in this ChIP and PCR analysis.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Treatment with 5-Aza-dC initiates demethylation by 12 h and transcription by 24 h at a hypermethylated hMLH1 promoter. RKO cells were treated with 1 μm 5-Aza-dC and harvested at the indicated time points. A, MSP analysis of hMLH1. A doubled line above the hMLH1 promoter schematic in Fig. 1A<$REFLINK> indicates the region examined by MSP. Methylation was detected by the presence of a PCR product amplified by methylation-specific primers in the M lanes. Demethylation was detected by PCR products amplified by unmethylated-specific primers in the U lanes. Bisulfite dH2O denotes bisulfite-treated dH2O, which served as a negative control for the treatment. RKO and SW480 served as positive controls for the methylated and unmethylated PCR reactions, respectively. B, reverse transcriptase-PCR analysis of hMLH1 expression. GAPDH expression served as a loading control. Five-day mock- and 5-day 5-Aza-dC-treated RKO cells served as negative and positive controls, respectively, for hMLH1 expression.

Tables

  • Figures
  • Table 1

    Summary of time course data

    Changes observed0 h12 h24 h48 h5 d
    DNA demethylationNoYesYesYesYes
    Gene reexpressionNoNoYesYesYes
    Acetylated H3↓a↓↓↑↑
    Methyl-H3-K4↓↓↓↑↑
    Methyl-H3-K9↑↑↑↓↓
    • a ↓, depletion; ↑, enrichment.

PreviousNext
Back to top
Cancer Research: 62 (24)
December 2002
Volume 62, Issue 24
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dependence of Histone Modifications and Gene Expression on DNA Hypermethylation in Cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dependence of Histone Modifications and Gene Expression on DNA Hypermethylation in Cancer
Jill A. Fahrner, Sayaka Eguchi, James G. Herman and Stephen B. Baylin
Cancer Res December 15 2002 (62) (24) 7213-7218;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dependence of Histone Modifications and Gene Expression on DNA Hypermethylation in Cancer
Jill A. Fahrner, Sayaka Eguchi, James G. Herman and Stephen B. Baylin
Cancer Res December 15 2002 (62) (24) 7213-7218;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Down-Regulation of Regulatory Subunit Type 1A of Protein Kinase A Leads to Endocrine and Other Tumors
  • Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
  • Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7
Show more Advances in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement